Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16533945 | 0.89 | SYK (0.53) | ALDH1A1KDM4EPOLBTP53SMN1; SMN2 | |
| SCHEMBL15720776 | 0.89 | ALDH1A1 (0.60) | ALDH1A1KDM4EPOLBTP53ALOX15 | |
| SCHEMBL15517531 | 0.88 | EPHX2 (0.53) | ALDH1A1KDM4EPOLBTP53ALOX15 | |
| SCHEMBL16533977 | 0.88 | SMN1; SMN2 (0.55) | ALDH1A1KDM4ETP53SMN1; SMN2GAA | |
| SCHEMBL16533854 | 0.86 | SMN1; SMN2 (0.50) | ALDH1A1KDM4EPOLBTP53ALOX15 | |
| SCHEMBL16566606 | 0.85 | EPHX2 (0.50) | ALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL16533920 | 0.85 | SMN1; SMN2 (0.49) | ALDH1A1KDM4EPOLBTP53ALOX15 | |
| SCHEMBL7323017 | 0.84 | ATM (0.63) | ALDH1A1KDM4ETP53SMN1; SMN2GAA | |
| SCHEMBL385247 | 0.84 | KDM4E (0.62) | ALDH1A1KDM4ETP53SMN1; SMN2GAA | |
| SCHEMBL63569 | 0.83 | SMN1; SMN2 (0.72) | ALDH1A1KDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| EP-2925742-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20150329523-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2925742-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015024905-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | ALDH1A1 1001/4885KDM4E 2115/4885POLB 1792/4885 |
| US-20150329523-A1 | KINASE INHIBITORS | SYK, SRC, BTK | ALDH1A1 4202/4885KDM4E 2536/4885POLB 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.